Eli Lilly launches Tanstrive, a targeted oral cancer therapy for RET-altered tumors, priced at ₹2.15 lakh for two weeks.

The launch follows marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for patients with locally advanced or metastatic solid tumours with a…

Eli Lilly launches Tanstrive, a targeted oral cancer therapy for RET-altered tumors, priced at ₹2.15 lakh for two weeks.